Violetta Cotreau - Feb 28, 2022 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role: SVP, Chief Accounting Officer
Signature: /s/ Carolyn Rucci, attorney-in-fact for Violetta Cotreau
Stock symbol: AKBA
Transactions as of: Feb 28, 2022
Transactions value $: -$8,503
Form type: 4
Date filed: 3/2/2022, 08:12 PM
Previous filing: Jan 5, 2022
Next filing: May 16, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKBA	Common Stock	Sale	-$8.5K	-3.95K	-11.93%	$2.15	29.1K	Feb 28, 2022	Direct	F1
transaction	AKBA	Common Stock	Award	$0	+40.8K	+140.22%	$0.00	70K	Feb 28, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKBA	Employee Stock Option (Right to buy)	Award	$0	+70K		$0.00	70K	Feb 28, 2022	Common Stock	70K	$2.16	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
F2	The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will become vested on the first anniversary of the grant date; and the remaining 2/3 of the Shares will vest in substantially equal quarterly installments thereafter, at the beginning of each of the following eight calendar quarters, subject to the reporting person's continued service with the Issuer on each vesting date.
F3	The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.